Pasar al contenido principal

PAPEL DE NGFR EN LAS CELULAS INICIADORAS DE LA METASTASIS Y EN LA EVASION DEL SISTEMA INMUNE

PID2020-118558RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NGFR regulates stromal cell activation in germinal centers

  • Hernández-Barranco, Alberto
  • Santos, Vanesa
  • Mazariegos, Marina S.
  • Caleiras, Eduardo
  • Nogués, Laura
  • Mourcin, Fréderic
  • Léonard, Simon
  • Oblet, Christelle
  • Genebrier, Steve
  • Rossille, Delphine
  • Benguría, Alberto
  • Sanz, Alba
  • Vázquez, Enrique
  • Dopazo, Ana
  • Efeyan, Alejo
  • Ortega-Molina, Ana
  • Cogne, Michel
  • Tarte, Karin
  • Peinado, Héctor
Nerve growth factor receptor (NGFR) is expressed by follicular dendritic cells (FDCs). However, the role of NGFR in the humoral response is not well defined. Here, we study the effect of Ngfr loss on lymph node organization and function, demonstrating that Ngfr depletion leads to spontaneous germinal center (GC) formation and an expansion of the GC B cell compartment. In accordance with this effect, stromal cells are altered in Ngfr mice with a higher frequency of FDCs, characterized by CD21/35, MAdCAM-1, and VCAM-1 overexpression. GCs are located ectopically in Ngfr mice, with lost polarization together with impaired high-affinity antibody production and an increase in circulating autoantibodies. We observe higher levels of autoantibodies in Bcl2 Tg/Ngfr mice, concomitant with a higher incidence of autoimmunity and lower overall survival. Our work shows that NGFR is involved in maintaining GC structure and function, participating in GC activation, antibody production, and immune tolerance., This work was supported by project PID2020-118558RB-I00 (State Research MCIN/AEI/10.13039/501100011033), based on previous work unded by RETOS SAF2017-82924-R (MCIN/AEI/10.13039/501100011033 and cofounded by the European Regional Development fund [ERDF-EU]), and PDC2021-121102-I00 (MCIN/AEI/10.13039/501100011033, European Union ‘‘NextGenerationEU’’/PRTR). We thank ‘‘la Caixa’’ Foundation (fellowship ID100010434, LCF/BQ/DE17/11600007) and EMBO scientific exchange grant (number 9156) awarded to A.H.-B. The CNIO, certified as a Severo Ochoa Center of Excellence, is supported by the Spanish Government through the Instituto de Salud Carlos III (ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma

  • García-Agulló, Juan
  • Santos, Vanesa
  • Garcia-Mayea, Yoelsis
  • de Luxan-Delgado, Beatriz
  • Bataller, Marina
  • Lleonart, Matilde Esther
  • Rodrigo, Juan P
  • García-Pedrero, Juana M
  • Álvarez-Fernández, Mónica
  • Peinado, Héctor
Supplementary data to this article can be found online at https://doi.org/10.1016/j.oraloncology.2026.108080, Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high mortality rates, often exhibiting resistance to conventional treatments such as radiotherapy (RT) or a combination of chemotherapy and radiotherapy (CRT). The nerve growth factor receptor (NGFR, also known as p75NTR or CD271) is a well-established cancer stem cell marker in melanoma, where it has been linked to resistance to multiple therapies. In HNSCC, NGFR has been reported as a poor prognostic marker, with its overexpression associated with disease progression. However, its contribution to therapy resistance in HNSCC remains unknown., Research in the laboratory of Dr Peinado is supported by grants from Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación / State Research Agencia Financiadora (AEI − Ministry of Science and Innovation: PID2020-118558RB-I00 (MICIU/AEI/https://doi.org/10.13039/501100011033), RETOS SAF2017-82924-R (AEI/https://doi.org/10.13039/501100011033/FEDER-UE), PDC2021-121102-I00 (MCIN/AEI/https://doi.org/10.13039/501100011033, European Union “NextGenerationEU”/PRTR), PID2023-147503OB-I00 funded by MCIU/AEI /https://doi.org/10.13039/501100011033 and by the European Union, ERDF “A way of making Europe”, Fundación Científica AECC (PRYCO223002PEIN, LABAE19027PEIN), the Mission Cancer within HORIZON EU Programme (PANCAID-101096309) and Fundación Ramón Areces. J.G.-A. was supported by Fundación Científica de la Asociación Española Contra el Cáncer (Predoctoral AECC 2021, PRDMA21602GARC). J.M.G.-P. and J.P.R. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI22/00167, PI25/00107 and CIBERONC (CB16/12/00390) and were co-funded by the European Union. J.M.G.-P. and J.P.R. are funded by the Government of the Principality of Asturias through the Agency for Science, Business Competitiveness and Innovation of the Principality of Asturias and co-financed by the European Union (IDE/2024/000778). M.A.-F. was supported by grant CNS2023-1444–73 funded by MCIU/AEI/https://doi.org/10.13039/501100011033 and “EuropeanUnionNextGenerationEU/PRTR” and by the Scientific Foundation of the Spanish Association against Cancer (LABAE235202ALVA). M.E. LL. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI24/00630 and AC24/00057, the latter under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme)., Peer reviewed, Sin experimentacion animal ni uso de NAMs